California Institute for Regenerative Medicine and the Davos Alzheimer’s Collaborative Release a Statement of Interest to Advance Brain Research
Contact: Drew Holzapfel: dholzapfel@highlanterngroup.com | Kevin McCormack: kmccormack@cirm.ca.gov
Geneva, January 26, 2022 – Today the Davos Alzheimer’s Collaborative (DAC) announced the California Institute for Regenerative Medicine’s (CIRM) interest in working with DAC on a shared mission to accelerate the discovery, assessment, and delivery of precision and effective therapeutic interventions for diseases of the brain, including Alzheimer’s disease.
CIRM, created and based in California, is the world’s largest institution dedicated to helping people by bringing the future of cellular medicine closer to reality. CIRM, was created in 2004 with a $3B bond funding under Proposition 71 which was enacted by voters to support stem cell research in California. In 2020, California voters approved the passage of Proposition 14, which dedicates $1.5B for the support of research and the development of treatments for diseases and conditions of the central nervous system, such as Alzheimer’s disease and Parkinson’s disease.
“CIRM is a global pioneer in innovative research at scale,” said George Vradenburg, Founding Board Chairmen of the Davos Alzheimer’s Collaborative. “Their commitment to brain health will ensure that we make progress against neurological conditions and address the toll these diseases have on individuals, families and societies.”
DAC is developing a cohort of 1 million people to provide a comprehensive data resource that is racially and ethnically inclusive and truly global in scope to analyze for scientific discovery. The program will aggregate current research data and support new data collection from teams of researchers across the globe.
“We share DAC’s vision of an aligned worldwide effort to understand the disease’s risk factors and find therapies,” said Jonathan Thomas, Chairman of the CIRM Board. “CIRM applauds DAC’s efforts to gather data from diverse populations. This is consistent with CIRM’s commitment to DEI in research. We are looking forward to more discussion about our potential future together.”
About CIRM
At CIRM, we never forget that we were created by the people of California to accelerate stem cell treatments to patients with unmet medical needs, and act with a sense of urgency to succeed in that mission.
To meet this challenge, our team of highly trained and experienced professionals actively partners with both academia and industry in a hands-on, entrepreneurial environment to fast track the development of today’s most promising stem cell technologies.
With $5.5 billion in funding and more than 150 active stem cell programs in our portfolio, CIRM is the world’s largest institution dedicated to helping people by bringing the future of cellular medicine closer to reality. For more information go to www.cirm.ca.gov
About the Davos Alzheimer’s Collaborative
Initiated in Davos, Switzerland, during the World Economic Forum’s Annual Meeting in 2020, The Davos Alzheimer’s Collaborative is a public-private partnership committed to aligning stakeholders with a new vision for our collective global response against the challenges Alzheimer’s presents to patients, caregivers, and healthcare infrastructures. Led by The World Economic Forum (WEF) and The Global CEO Initiative on Alzheimer’s Disease (CEOi) and fueled by a mission of service to the 150 million families and half a billion people inevitably impacted by this disease by 2050, DAC is a collaborative for the benefit of all people, in all places.
